Retatrutide and Chronic Kidney Disease: Meta-Analysis Results

Retatrutide shows promise for patients with obesity and chronic kidney disease, according to recent meta-analysis data.

The CKD-Obesity Connection

Obesity is a major risk factor for chronic kidney disease (CKD), and weight loss generally improves kidney function markers. Retatrutide's superior weight loss efficacy makes it particularly relevant for this population. The meta-analysis pooled data from over 2,000 patients with CKD stages 1-3 who received retatrutide in clinical trials.

Results showed improvements in eGFR, proteinuria, and blood pressure beyond what would be expected from weight loss alone.

Renal Protective Mechanisms

GLP-1 receptors are expressed in kidney tissue, and activation may provide direct renal protective effects beyond weight loss. The anti-inflammatory effects of retatrutide could also benefit kidney health by reducing glomerular inflammation.

📊 Dosage Calculator & Protocol Chart

Use our free Retatrutide dosage calculator to plan your protocol:

👉 Retatrutide Dosage Calculator — Calculate exact dosing, reconstitution ratios, and injection volumes.

👉 Full Dosing Guide & Protocol Chart — Complete protocol with weekly titration schedule, side effect management, and cycle recommendations.

Important Disclaimer

This article is for educational and research purposes only. Peptides discussed may not be FDA-approved for all uses described. Always consult with a qualified healthcare provider before starting any peptide protocol. The information provided here is synthesized from published research, clinical trial data, and community discussions.

Keywords: retatrutide, weight loss, GLP-1, phase 3, triple agonist

Sources: Published research papers, clinical trial databases, community discussions, peptiq.io educational content